Sermorelin.
GHRH analogue that prompts the pituitary to release endogenous growth hormone in physiological pulses.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About Sermorelin.
Sermorelin is a 29-amino-acid synthetic analogue of the first 29 residues of human growth-hormone-releasing hormone (GHRH 1-29). It was the first GHRH analogue approved in clinical use and remains a reference molecule for stimulating endogenous GH release.
Unlike exogenous recombinant human growth hormone (rhGH), Sermorelin acts upstream of the pituitary: it asks the somatotrophs to release the GH they already produce. This preserves the negative-feedback loop with somatostatin and IGF-1, which is why most clinicians regard it as a safer long-term option than supraphysiological rhGH dosing.
Sermorelin binds to the GHRH receptor (GHRHR) on pituitary somatotrophs, increasing intracellular cAMP and triggering the release of stored growth hormone in a physiological, pulsatile pattern. The pulses align with the body's natural circadian GH peaks, primarily during slow-wave sleep.
Subcutaneous injection, typically once daily before sleep. Common doses range from 100 to 300 mcg per administration, titrated by the physician based on response and IGF-1 monitoring. Cycles of 3–6 months are followed by clinical re-evaluation.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Walker RF — Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging · 2006 · doi: 10.2147/ciia.2006.1.4.307
- INN / Name
- Sermorelin
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Growth Hormone.
- Cat. 03
Ipamorelin
Selective ghrelin-receptor agonist with minimal cortisol or prolactin elevation.
€45.00 - Cat. 03
GHRP-6
First-generation GH-releasing hexapeptide with appetite-stimulating side effect.
€50.00 - Cat. 03
CJC-1295
GHRH analogue — DAC variant gives sustained release, NO-DAC mimics native pulsatility.
€80.00